oleclumab,ceralasertib,durvalumab,olaparib,danvatirsen,trastuzumab deruxtecan,cediranib,vistusertib
merck,astrazeneca,daiichi sankyo
['hudson']
hudson #aacr23 second exemplar - anthracylin-related cardiotoxicity. cardiac events and congestive heart failure increasing at +15, +20, +30 years. '16 ref 
Business development, marketing and sales professional in the life sciences, cancer diagnostics, and genomics fields. Blog: https://t.co/IeMzCogxlt. Opinions are my own.